Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis reveal growth hormone pre-treatment enhances uterine size in Turner syndrome, suggesting potential benefits for puberty induction.
Background: Girls with Turner syndrome (TS) often have delayed or absent puberty from gonadal dysgenesis. Puberty induction with oestrogen is standard, but uterine development is frequently impaired. Growth hormone (GH), used for short stature in TS, may also enhance uterine growth. Objective: To evaluate the effect of GH pre-treatment on uterine size in girls with TS. Search strategy: PubMed, Embase and Cochrane CENTRAL were searched from inception to August 2025. Selection criteria: Eligible studies compared uterine size in TS girls who received GH before oestrogen induction with those who did not. Data collection and analysis: Two authors independently screened studies and extracted data. Quality was assessed using the Cochrane ROBINS-I tool. Random-effects meta-analysis was performed, and certainty of evidence graded with the GRADE approach. Main results: Three observational studies (182 participants) met inclusion criteria. Meta-analysis showed GH pre-treatment increased uterine length by 1.01 cm (95% CI −0.43–2.45; I 2 = 90%). Sensitivity analysis, excluding one study at serious risk of bias, showed a more consistent effect, with a pooled mean difference of 1.83 cm (95% CI 1.34 to 2.32; I 2 = 0%). Conclusion: Our findings suggest that GH pre-treatment appears to promote uterine growth; however, the certainty of evidence is low. To our knowledge, this is the first systematic review and meta-analysis to address this question. Robust, well-designed studies are required to confirm these observations and better define the clinical role of GH in this context.
No takes yet. Share an insight, caveat, or question.
Raza et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: